Form 4: Arrowhead Director Sells Shares Under 10b5-1 Plan

Arrowhead Pharmaceuticals Director Adeoye Y Olukotun sold 9,990 shares of common stock on December 19, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Director Adeoye Y Olukotun of Arrowhead Pharmaceuticals, Inc. (ARWR) reported the sale of common stock.
• The transactions occurred on December 19, 2025.
• A total of 9,990 shares were sold across three separate transactions.
• The sales were executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person.
• The first transaction involved 3,090 shares sold at a weighted average price of $66.70, with individual prices ranging from $66.52 to $67.40.
• The second transaction involved 6,083 shares sold at a weighted average price of $68.04, with individual prices ranging from $67.62 to $68.30.
• The third transaction involved 827 shares sold at a weighted average price of $68.48, with individual prices ranging from $68.38 to $68.56.
• Following these transactions, the reporting person beneficially owns 33,600 shares of common stock.
• The beneficially owned shares include previously reported common stock underlying Restricted Stock Units, a portion of which are still subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the disclosure that these sales were made under a pre-arranged 10b5-1 trading plan suggests a scheduled financial planning event rather than a reaction to new, adverse company-specific information. This mitigates immediate negative implications.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction rather than an immediate reaction to new, potentially negative, company information.

Negatives

• Director Adeoye Y Olukotun reduced direct beneficial ownership by 9,990 shares.
• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially leading to short-term downward pressure on the stock price.

Future Outlook

This filing, a Form 4, reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request to Arrowhead Pharmaceuticals, Inc., any security holder, or the SEC staff.

Industry Context

This Form 4 filing is specific to an insider transaction at Arrowhead Pharmaceuticals and does not provide broader industry trends or competitive analysis. Insider trading reports are a standard disclosure requirement across all publicly traded industries.

Stakeholder Impact

• Shareholders may note the reduction in direct ownership by a director. However, the context of a 10b5-1 plan suggests these are pre-planned financial decisions, which typically have less impact on investor sentiment compared to unscheduled sales.

Key Dates

Recommendation

A single insider sale, even by a director, when executed under a pre-arranged 10b5-1 trading plan, is generally considered a routine personal financial management event. It does not typically signal a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this filing. Investors should consider this transaction in the broader context of the company's performance, industry trends, and other financial disclosures.

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director Transaction, Adeoye Y Olukotun